Resistance and infection case analysis for multidrug-resistant Acinetobacter baumannii
10.3760/cma.j.issn.1009-9158.2013.08.017
- VernacularTitle:多重耐药鲍曼不动杆菌耐药性及感染病例分析
- Author:
Xiaoyong XU
;
Jianrong SU
- Publication Type:Journal Article
- Keywords:
Acinetobacter baumannii;
Drug resistance,multiple,bacterial;
Acinetobacter infections;
Drug therapy,combination
- From:
Chinese Journal of Laboratory Medicine
2013;36(8):748-751
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the resistance and infection case for the Multidrug-Resistant Acinetobacter baumanii (MDRAb) strains.Methods Retrospective study.Thirty-eight MDRAb strains were collected in Beijing Friendship Hospital from February to August 2008.VITEK2-compact system was used to detect the MDRAb.PCR was carried out to detect their resistance related genes and look up the medical records those who were infected by MDRAb.Results The resistance rate of the MDRAb is the highest in ICU.PCR confirmed that OXA-23 and OXA-51 were 100％ related with the MDRAb.Combination drug therapy such as sulbactam combined with β-lactam antibiotics was more effective than β-lactam antibiotics only to treat the infection with MDRAb.Cases analysis showed that a number of patients infected by MDRAb were the aged with basic diseases,low immunity,received a variety of antibiotic therapy even traumatic operation,and they had a poor prognosis finally.Conclusions The resistance rate of the MDRAb is the highest in ICU,OXA-23 is closely related to multidrug-resistance.Combination drug therapy is necessary and sulbactam can play a great role in curing the inpatients infected with MDRAb.
